Echoes of the Week: Expert Insights on AI, Diagnostics, and Health Policy

Elisabeth Bik, PhD, a scientific integrity consultant, stated regarding artificial intelligence-generated research papers, “We are at a point now that we cannot distinguish fake from real.”

Andrew Peterson, MD, of Duke University Medical Center in Durham, North Carolina, commented on men’s aversion to conventional artificial urinary sphincters with scrotal control pumps, noting, “They want to know whether they have to, basically, ‘mash on my junk.'”

Victor van Berkel, MD, PhD, of UofL Physicians in Louisville, Kentucky, addressed an FDA advisory committee discussion on a multicancer early detection blood test, asking, “It can detect things early … earlier than maybe we would find in some circumstances. But is that clinically relevant?”

Helen Tager-Flusberg, PhD, of Boston University, expressed optimism regarding an HHS-led research initiative aimed at changing how autism is diagnosed, stating, “I am optimistic that this could be transformative.”

Ross Boyce, MD, of the University of North Carolina at Chapel Hill, discussed the growing challenges of diagnosing Lyme disease and other tick-borne coinfections, observing, “It’s getting messier and messier as northern ticks are migrating south, and the ticks that are down here have migrated north.”

Sarah Wetter, JD, MPH, of the O’Neill Institute’s Center for Health Policy and the Law in Washington, D.C., addressed how a federal appeals court ruling on mifepristone (Mifeprex) regulation could impact nationwide abortion access, stating, “A decision for Louisiana would impose one state’s abortion policy on the rest of the country.”

Keith Flaherty, MD, AACR President and of the Mass General Brigham Cancer Institute in Boston, discussed a report showing a 35% drop in overall U.S. cancer mortality since 1991, warning, “The current turmoil at NIH and other federal health agencies threatens continued progress for patients.”

Brian Callaghan, MD, MS, of the University of Michigan in Ann Arbor, commented on a study showing gabapentin prescribing surged after Michigan descheduled the drug, asserting, “The downsides to gabapentin are quite small and are not enough to warrant being a scheduled medication.”

Source link